Achieve Life Sciences, Inc. held its 2026 Annual Meeting of Stockholders, where stockholders voted on several key items, including the election of nine directors, ratification of PricewaterhouseCoopers as the independent auditor, and a non-binding advisory vote on executive compensation. A significant proposal was to double the company’s authorized common shares from 150 million to 300 million, which could enhance flexibility for future financing. CEO Andrew Goldberg chaired the meeting, confirming that majority voting stock was represented, and results will be reported within four business days. Achieve focuses on developing cytisinicline, a therapy for smoking cessation.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://finance.yahoo.com/markets/stocks/articles/achieve-life-sciences-stockholders-weigh-000153702.html
